5E
5EA.F Elanco Animal Health Inc
- Market cap
- EUR 11.9B
- P/E
- -
- P/B
- 2.00x
- ROE
- 2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5EA.F undervalued?
Graham numberThe Graham number of Elanco Animal Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elanco Animal Health Inc fundamental analysis
No fundamental analysis for Elanco Animal Health Inc yet.
Elanco Animal Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elanco Animal Health Inc
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of f…
Full company profileElanco Animal Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elanco Animal Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.91B | 2.89B | 3.07B | 3.07B | 3.27B | 4.77B | 4.42B | 4.42B | 4.44B | 4.72B | 5.34B |
| Gross Profit | 1.50B | 1.40B | 1.49B | 1.60B | 1.61B | 2.63B | 2.51B | 2.49B | 2.44B | 2.59B | 3.07B |
| Operating Income | 283M | 142M | 314M | 370M | -76.8M | 302M | 390M | 326M | 251M | 252M | 495M |
| EBITDA | - | 461M | 440M | 472M | -5.30M | 225M | 703M | -224M | 1.39B | 676M | 1.15B |
| Net Income | -47.9M | -311M | 86.5M | 67.9M | -560M | -472M | -74.0M | -1.23B | 338M | -232M | 172M |
| EPS | - | -0.87 | 0.24 | 0.18 | -1.19 | -1.00 | -0.16 | -2.50 | 0.68 | -0.47 | 0.34 |
| Balance Sheet | |||||||||||
| Total Assets | 8.10B | 8.94B | 8.96B | 8.99B | 17.7B | 16.5B | 15.5B | 14.4B | 12.6B | 13.4B | 13.3B |
| Total Liabilities | 1.07B | 1.15B | 3.76B | 3.44B | 9.22B | 8.95B | 8.20B | 8.14B | 6.52B | 6.81B | 6.71B |
| Shareholders' Equity | 7.03B | 7.79B | 5.20B | 5.55B | 8.48B | 7.54B | 7.29B | 6.22B | 6.10B | 6.55B | 6.63B |
| Cash & Short-term Investments | 259M | 323M | 475M | 334M | 495M | 638M | 345M | 352M | 468M | 545M | 465M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 156M | 174M | 487M | 224M | -41.0M | 483M | 452M | 271M | 541M | 560M | 675M |
| Capital Expenditure | 110M | 98.6M | 135M | 140M | 135M | 126M | 137M | 140M | 147M | 276M | 192M |
| Free Cash Flow | - | 75.2M | 353M | 26.7M | -352M | 286M | 268M | 131M | 394M | 284M | 483M |
| Ratios | |||||||||||
| ROE | -0.7% | -4.0% | 1.7% | 1.2% | -6.6% | -6.3% | -1.0% | -19.8% | 5.5% | -3.5% | 2.6% |
| ROA | -0.6% | -3.5% | 1.0% | 0.8% | -3.2% | -2.9% | -0.5% | -8.6% | 2.7% | -1.7% | 1.3% |
| Net Profit Margin | -1.6% | -10.8% | 2.8% | 2.2% | -17.1% | -9.9% | -1.7% | -27.9% | 7.6% | -4.9% | 3.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Elanco Animal Health Inc dividends
Elanco Animal Health Inc has not paid dividends in the last 9 fiscal years.
Who owns Elanco Animal Health Inc
- Insiders 1.21%
- Institutions 98.79%
- Public & others 0.00%
- Shares outstanding 500M
- Free float 496M
Elanco Animal Health Inc company profile
- Company name
- Elanco Animal Health Inc
- Ticker
- 5EA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9,400
- Fiscal year end
- December
- Address
- 450 Elanco Circle, Indianapolis, IN, United States, 46221
- Phone
- 877 352 6261
- Website
- elanco.com
About Elanco Animal Health Inc
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Elanco Animal Health Inc management
10- Mr. Jeffrey N. SimmonsPresident, CEO & Director · born 1967
- Mr. Robert M. VanHimbergenExecutive VP & CFO · born 1976
- Dr. Ramiro Martin CabralExecutive VP & President of Elanco International · born 1972
- Dr. Ellen de Brabander Ph.D.Executive Vice President of Research, Development & Regulatory Affairs · born 1963
- Mr. Timothy J. BettingtonExecutive Vice President of Center of Strategic Growth · born 1974
- Mr. James M. MeerSenior VP & Chief Accounting Officer · born 1970
- Mr. David S. KinardExecutive Vice President of Human Resources, Corporate Communications & Administration · born 1967
- Ms. Tiffany Ann KanagaVP of Investor Relations & ESG
- Ms. Shiv O'NeillExecutive Vice President, General Counsel & Corporate Secretary · born 1975
- Mr. Larbi Van LierSenior Vice President of Asia